Cargando…

The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial

AIM: To undertake a cost‐effectiveness analysis of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus (T2DM), using both directly observed events in the DECLARE‐TIMI 58 trial and surrogate risk factors to predict endpoints not captured within the trial. METHODS: An establishe...

Descripción completa

Detalles Bibliográficos
Autores principales:	McEwan, Phil, Morgan, Angharad R., Boyce, Rebecca, Bergenheim, Klas, Gause‐Nilsson, Ingrid A.M., Bhatt, Deepak L., Leiter, Lawrence A., Johansson, Peter A., Mosenzon, Ofri, Cahn, Avivit, Wilding, John P.H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048502/ https://www.ncbi.nlm.nih.gov/pubmed/33368855 http://dx.doi.org/10.1111/dom.14308

Ejemplares similares

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
por: Mosenzon, Ofri, et al.
Publicado: (2022)

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
por: Bergmark, Brian A., et al.
Publicado: (2018)

Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study
por: Escobar, Carlos, et al.
Publicado: (2022)

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study
por: Norhammar, Anna, et al.
Publicado: (2019)

Dapagliflozin vs non‐SGLT‐2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE‐TIMI 58 trial: A nationwide observational study
por: Norhammar, Anna, et al.
Publicado: (2019)

SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins
por: Singh, Awadhesh K., et al.
Publicado: (2019)

Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
por: McEwan, Phil, et al.
Publicado: (2020)

Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK
por: Bennett, Hayley, et al.
Publicado: (2014)

The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus
por: McEwan, Phil, et al.
Publicado: (2016)

A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
por: Berg, David D., et al.
Publicado: (2021)

Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model
por: McEwan, Philip, et al.
Publicado: (2015)

Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
por: Charokopou, M., et al.
Publicado: (2015)

Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension
por: Cefalu, William T., et al.
Publicado: (2015)

Dynamic TIMI Risk Score for STEMI
por: Amin, Sameer T., et al.
Publicado: (2013)

Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs: When and for whom?
por: Mosenzon, Ofri, et al.
Publicado: (2013)

Early Insulinization to Prevent Diabetes Progression
por: Raz, Itamar, et al.
Publicado: (2013)

From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
por: Sonesson, Christian, et al.
Publicado: (2016)

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
por: Heerspink, H. J. L., et al.
Publicado: (2016)

Paving the way to precision medicine for diabetic kidney disease: the PRIORITY trial
por: Schechter, Meir, et al.
Publicado: (2020)

Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A narrative review and proposed clinical approach
por: Schechter, Meir, et al.
Publicado: (2022)

Importance of the TIMI frame count: implications for future trials
por: Appleby, Mark A, et al.
Publicado: (2000)

TIMI perfusion grade compared to TIMI flow in prediction of infarct size and microvascular obstruction measured by contrast-enhanced MRI
por: Fuernau, Georg FK, et al.
Publicado: (2009)

A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol
por: Brown, Emily, et al.
Publicado: (2021)

Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
por: Bonaca, Marc P., et al.
Publicado: (2018)

Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme
por: Gordon, Jason, et al.
Publicado: (2020)

Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA(1c), weight and hypoglycaemic event incidence
por: McEwan, P., et al.
Publicado: (2018)

Diabetes and Stroke: What Are the Connections?
por: Mosenzon, Ofri, et al.
Publicado: (2023)

Implications of the PEGASUS-TIMI 54 trial for US clinical practice
por: Bradley, Steven M, et al.
Publicado: (2017)

Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
por: Cahn, Avivit, et al.
Publicado: (2016)

Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
por: Waijer, Simke W., et al.
Publicado: (2022)

Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial
por: Bergmark, Brian A., et al.
Publicado: (2021)

A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
por: Wilding, John P.H., et al.
Publicado: (2009)

Declarations
Publicado: (2015)

Far Beyond Declarative and Non-Declarative Memories
por: Dere, Ekrem, et al.
Publicado: (2014)

The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic review
por: Bem, Danai, et al.
Publicado: (2021)

Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults
por: Schechter, Meir, et al.
Publicado: (2022)

Vaccinating Adolescents and Children Significantly Reduces COVID-19 Morbidity and Mortality across All Ages: A Population-Based Modeling Study Using the UK as an Example
por: Shiri, Tinevimbo, et al.
Publicado: (2021)

The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program
por: Shiri, Tinevimbo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mfhbv0ee22fcp7btr14hjfl6l3